Table 1.
Demographic and clinical characteristics of study participants.
| PD (n = 33) | Controls (n = 12) | |
|---|---|---|
| Age at assessment (years, mean ± SD) | 69.8 ± 8.7 | 60.8 ± 9.8 |
| Sex (numbers male/female) | 29/4 | 1/11 |
| Time since diagnosis (years mean ± SD) | 5.2 ± 4.6 | Not applicable |
| Hoehn and Yahr Scale (mean ± SD) * | 2.2 ± 0.7 | 0 |
| MDS-UPDRS I total score (mean ± SD) | 9.1 ± 4.6 | 7.9 ± 7.3 |
| MDS-UPDRS II total score (mean ± SD) | 10.5 ± 7.1 | 1.3 ± 2.8 |
| MDS-UPDRS III total score (mean ± SD) * | 40.9 ± 12.7 | 4.8 ± 3.5 |
| MDS-UPDRS IV total score (mean ± SD) | 1.5 ± 2.8 | 0 |
| Total sum of MDS-UPDRS I-IV (mean ± SD) | 61.9 ± 19.0 | 14.1 ± 10.9 |
| Montreal Cognitive Assessment (mean ± SD) * | 24.1 ± 3.5 | 27 ± 2.8 |
| Levodopa Equivalent Daily Dose (mean ± SD) | 499.1 ± 459.4 | Not applicable |
| Time since last L-DOPA intake (minutes mean ± SD) | 155.9 ± 113.1 | Not applicable |
* Assessment in medication ON state for PD.